Overview

Sevoflurane for Treatment-Resistant Depression

Status:
Not yet recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

This study intends to carry out a prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subanesthetic sevoflurane for treatment-resistant depression.

Phase:

N/A

Details

Lead Sponsor:

Shanghai First Maternity and Infant Hospital

Collaborator:

Shanghai Pudong New Area Mental Health Center

Treatments:

Sevoflurane